Maytansinoid B is a kind of apoptosis[1][2].
Maytansinoid 对包括淋巴瘤系在内的几种肿瘤细胞系表现出 10-90 pM 的细胞毒活性[1]。
Maytansinoid 与抗 CD9 抗体结合，可形成 SAR3419 对抗 B 细胞恶性肿瘤[1]。
[1]. Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011 Oct 15;17(20):6448-58.
[2]. Andreev Julian, et al. Bispecific antigen binding molecules that bind HER2, and methods of use thereof: World Intellectual Property Organization, WO2021174113. 2021-09-02.